Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Norepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.77 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.77 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.77 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.77 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.77 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.77 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.77 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.77 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 6/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | RECQL | P46063 | 3/20 | 0.77 |
| ▸ | APEX1 | P27695 | 3/20 | 0.77 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | DRD1 | P21728 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norfenefrine SCHEMBL15485360 | 0.89 | HIF1A (0.59) | BLMKDM4ETDP1LMNAMAPT | |
| Norfenefrine SCHEMBL9639702 | 0.89 | HIF1A (0.59) | BLMKDM4ETDP1LMNAMAPT | |
| Norfenefrine SCHEMBL153494 | 0.89 | HIF1A (0.59) | BLMKDM4ETDP1LMNAMAPT | |
| Norfenefrine SCHEMBL30389272 | 0.89 | HIF1A (0.59) | BLMKDM4ETDP1LMNAMAPT | |
| Norfenefrine SCHEMBL1797532 | 0.89 | HIF1A (0.59) | BLMKDM4ETDP1LMNAMAPT | |
| Norfenefrine SCHEMBL29394995 | 0.89 | HIF1A (0.59) | BLMKDM4ETDP1LMNAMAPT | |
| Norfenefrine SCHEMBL217926 | 0.88 | HIF1A (0.61) | BLMKDM4ETDP1LMNAMAPT | |
| Norfenefrine SCHEMBL1650723 | 0.88 | HIF1A (0.61) | BLMKDM4ETDP1LMNAMAPT | |
| Norepinephrine SCHEMBL2609 | 0.88 | TDP1 (1.00) | BLMKDM4ETDP1LMNAMAPT | |
| L-Norepinephrine SCHEMBL3489077 | 0.88 | TDP1 (1.00) | BLMKDM4ETDP1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2879666-B1 | FREE FLOWING, FROZEN COMPOSITIONS COMPRISING A THERAPEUTIC AGENT | TAVAKOLI ZAHRA (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20190125842-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | CHILDREN'S HOSPITAL MEDICAL CENTER | 2019-05-02 | — | — | US | disclosed |
| EP-1866323-B1 | GLUCURONIDATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1848424-B1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-12-22 | — | — | US | disclosed |
| EP-2879666-A1 | FREE FLOWING, FROZEN COMPOSITIONS COMPRISING A THERAPEUTIC AGENT | Tavakoli, Zahra (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20150140105-A1 | FREE FLOWING, FROZEN COMPOSITIONS COMPRISING A THERAPEUTIC AGENT | TAVAKOLI ZAHRA (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2808015-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140234288-A1 | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014022195-A1 | FREE FLOWING, FROZEN COMPOSITIONS COMPRISING A THERAPEUTIC AGENT | TAVAKOLI ZAHRA (US) | 2014-02-06 | — | — | WO | disclosed |
| EP-1890691-A2 | COMPOSITIONS COMRISING NEBIVOLOL | MYLAN LABORATORIES, INC (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1866323-A2 | GLUCURONIDATED NEBIVOLOL | MYLAN LABORATORIES, INC (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007030375-A2 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2007-03-15 | — | — | WO | disclosed |
| EP-1753418-A2 | COMPOSITIONS COMPRISING NEBIVOLOL | MYLAN LABORATORIES, INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070014733-A1 | Hydroxylated nebivolol metabolites | DEY PHARMA, L.P. (F/K/A DEY L.P.) | 2007-01-18 | — | — | US | disclosed |
| US-20070014734-A1 | Glucuronidated nebivolol metabolites | MYLAN INC. (F/K/A MYLAN LABORATORIES INC.) | 2007-01-18 | — | — | US | disclosed |
| WO-2006130174-A2 | COMPOSITIONS COMRISING NEBIVOLOL | MYLAN LABORATORIES, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006083780-A2 | GLUCURONIDATED NEBIVOLOL | MYLAN LABORATORIES, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2005117858-A2 | COMPOSITIONS COMPRISING NEBIVOLOL | MYLAN LABORATORIES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272810-A1 | Compositions comprising nebivolol | MYLAN INSTITUTION INC. (F/K/A UDL LABORATORIES, INC.) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234288-A1 | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases | LIPC, PNLIP, LIPA | ADRB2 3789/4885ADRB1 2322/4885ADRA2A 2690/4885 |
| US-20190125842-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | LIPC, PNLIP, LIPA | ADRB2 3770/4885ADRB1 2315/4885ADRA2A 2683/4885 |
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | LIPC, PNLIP, LIPA | ADRB2 3770/4885ADRB1 2315/4885ADRA2A 2683/4885 |
| US-20050272810-A1 | Compositions comprising nebivolol | ADRB1, ADRB3, ADRB2 | ADRB2 3/4885ADRB1 1/4885ADRA2A 11/4885 |
| US-20070014734-A1 | Glucuronidated nebivolol metabolites | UGT1A4, UGT1A3, UGT1A1 | ADRB2 23/4885ADRB1 7/4885ADRA2A 37/4885 |
| US-20070014733-A1 | Hydroxylated nebivolol metabolites | EDNRB, EDNRA, ADRB1 | ADRB2 6/4885ADRB1 3/4885ADRA2A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.